Anti-GSDMD antibody [EPR19829] (Ab210070)

DFNA5L, GSDMDC1, FKSG10, GSDMD, Gasdermin-D, Gasdermin domain-containing protein 1

反应种属:Human
抗原名称:GSDMD
应用:WB

用户验证的应用

推荐稀释比例

  • WB1/1000

详细信息

免疫原The exact immunogen used to generate this antibody is proprietary information.
宿主/亚型Rabbit / IgG
抗体类型Monoclonal
全称Anti-GSDMD antibody [EPR19829]
产品形式Liquid
储存缓冲液pH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
储存条件运输条件: Conditional Ambient 推荐的短期储存时间: 1-2 weeks 推荐的短期储存条件: +4°C 推荐的长期储存条件: -20°C 储存信息: Avoid freeze / thaw cycle
纯化方式Affinity purification Protein A

背景信息

Anti-GSDMD antibody [EPR19829] (ab210070) was developed by Abcam using patented rabbit monoclonal antibody technology and is validated for use in WB in human samples. Anti-GSDMD antibody [EPR19829] (ab210070) has been cited over 57 times in peer reviewed journals and is trusted by the scientific community. Abcams high quality manufacturing and validation processes ensure Anti-GSDMD antibody [EPR19829] (ab210070) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility. The specificity of Anti-GSDMD antibody [EPR19829] (ab210070) has been confirmed by testing in knockout samples. Anti-GSDMD antibody [EPR19829] (ab210070) specifically detects GSDMD (UniProt ID: P57764; Molecular weight: 53kDa) and is sold in 100 uL and 1 mL selling sizes. Conjugation-ready, carrier free format available for antibody clone EPR19829 - ab232485. GSDMD is crucial for mediating pyroptosis, a form of programmed cell death, and plays a significant role in inflammatory responses and immune defense against infections What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies.

文献引用 (121)

Aptamer-functionalized exosomes combined with doxorubicin suppress GBM progression and enhance chemoradiosensitivity by promoting pyroptosis.

适体功能化的外泌体与阿霉素联合使用,通过促进细胞焦亡抑制胶质母细胞瘤进展并增强化疗和放射敏感性。

Wang Jing, Peng Li, Zhong Xinxin, Zheng Siqi, Liang Xiuhua, Du Menghan, Xia Xiangning, Guo Ting, Zheng Lidan, Fang Yingying, Tian Yinghong, Shi Yusheng, Zhang Xingmei

Targeted Induction of Cancer Cell Necroptosis Potentiates Anti-PD-1 Immunotherapy via CD80 Activation.

靶向诱导癌细胞坏死性凋亡通过 CD80 激活增强抗 PD-1 免疫疗法。

Zhang Xu, Zhang Detian, Zhou Zhe, Liu Waner, Zhu Susi, Xiong Siyu, Chen Xiang, Peng Cong

The NLRP6 inflammasome is activated by sterile or pathogen-induced endolysosomal damage

NLRP6炎症小体可被无菌性或病原体诱导的内溶酶体损伤激活。

Alexandra Boegli,Elliott M Bernard,Louise Lacante,Gaël Majeux,Ella Hartenian,Vanessa Mack,Petr Broz

Redefining Shiga toxin-induced human cell death as NLRP1- and gasdermin E-mediated pyroptosis.

将志贺毒素诱导的人类细胞死亡重新定义为 NLRP1 和 gasdermin E 介导的细胞焦亡。

Ricci-Azevedo Rafael, Sarkar Bishajit, Shivcharan Sonia, Hazra Aadrita, Browne Mercy, Carlson Emma K, Chidambaram Udayan, Rathinam Vijay A, Kailasan Vanaja Sivapriya

An atom-edged magnetic nanomotor for cancer mechanotherapy.

用于癌症机械疗法的原子级磁性纳米马达。

Tao Feng, Li Yingze, Guo Zihan, Sun Chenkai, Wang Yingying, Hu Zhixiang, Lv Cheng, Fan Xinjian, Ning Peng, Chen Chang, Cheng Yu

HMGN2 induces pyroptosis in tumour cells by modulating the STT3B/PD‑L1/caspase‑1/GSDMD axis.

HMGN2 通过调节 STT3B/PD-L1/caspase-1/GSDMD 轴诱导肿瘤细胞焦亡。

Han Wenwen, Chen Hongli, Cui Bomiao, Chen Jiao, Zhang Ping, Feng Yun

CTSB mediates oxidative stress and intestinal epithelial barrier disruption in intestinal ischemia‑reperfusion injury.

CTSB介导肠缺血再灌注损伤中的氧化应激和肠上皮屏障破坏。

He Shuang, Wang Lei, Wang Zhe, Yu Shiyong, Zhu Qi, Xu Yijun, Jiang Yuhang, Wu Yingxia, Xiang Honggang

Activation of TRPV4 to drive pyroptosis-dependent orthodontic tooth remodeling.

激活 TRPV4 以驱动依赖于细胞焦亡的正畸牙齿重塑。

He Zhengquan, Tian Huan, Liu Xingyu, Duan Yige, Chen Mengshan, Luo Zhenyan

Aurora kinase B phosphorylates ZBP1 to drive PANoptosis following treatment with PARP and ATR inhibitors combination.

Aurora 激酶 B 磷酸化 ZBP1,在 PARP 和 ATR 抑制剂联合治疗后驱动 PANoptosis。

Gong Wenjian, Liao Zhiqi, Xiong Fan, Wang Linghui, Shi Shennan, Luo Mengshi, Zhang Yuewen, Xu Qiuyang, Wang Yuanyuan, Wu Yijie, Zhu Li, Kuang Dong, Labrie Marilyne, Mills Gordon B, Ma Ding, Liu Dan, Zhao Guang-Nian, Gao Qinglei, Fang Yong

RING1 dictates GSDMD-mediated inflammatory response and host susceptibility to pathogen infection.

RING1 决定 GSDMD 介导的炎症反应和宿主对病原体感染的易感性。

Li Yuanyuan, Gao Wenqing, Qiu Yuxin, Pan Jiasong, Guo Qingqing, Liu Xuehe, Geng Lu, Shen Yajie, Deng Yifan, Hu Zhidong, Li Suhua, Liu Shanshan, Idris Adi, Huang Jinqing, Yang Hua, Ge Baoxue, Fan Xiaoyong, Chen Xiangjun, Li Jixi
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 13